摘要
目的研究Craves病(GD)131I治疗个体化剂量方法。方法 177例按吸收剂量计算131I治疗剂量的病人,对比其治疗前后示踪和治疗剂量的甲状腺吸碘率(RAIU)和有效半衰期(EHL)的差别,治疗前后甲状腺体积由核素显像(RI)及B超(BUS)重复测量,抗体检测。结果 177例中,131I一次治愈144例,占81.4%,甲功正常110例,占62.1%,早发甲减34例,占19.2%;未愈33例,占18.6%。治疗前后24hRAIU(76.9±8.90)%和(73.9±10.9)%(t=2.69,P<0.01)、EHL(5.2±0.8)d(n=177)和(5.0±0.6)d(n=165)(t=2.62,P<0.01)。抗体阳性甲减率28.5%高于阴性组12.1%(χ2=8.2,P<0.01)。结论 GD131I治疗前质量起决定作用;治疗剂量131I RAIU和EHL低于示踪剂量;甲状腺抗体阳性对疗效有影响。
Objective To study the individual radiation dose for iodine-131 used to treatment Graves＇disease. Meth- ods A total of 177 patients with Graves＇disease were selected. 1311 tracer radioactive iodine uptake （RAIU）＆ effective half-life （EHL） were compared with therapeutic dose. Thyroid weigh were estimated by radionuclide imaging （RI） ＆ type B Ultrasonography（BUS）before ＆ after 131I therapy. Thyroid function ＆ antibody was determined by serum level. Results The RAIU of tracer dose＆therapeutic 131I dose were （76.9±8.9）% ＆ （73.9±10.9）%（t=2.69,P〈0.01）： the EHL （5.2±0.8） （n= 177） ＆ （5.0±0.6） days（n=165） （t=2.62, P〈0.01）. The thyroid weigh after 131I treatment was significantly decreased. 110 patients appeared euthyroid,34 occurd early hypothyroidism,33 were still hyperthy- roidism. Hypothyroidism in thyroid anti-body positive was 28.5% compared 12.1% with negative （X2=8.2,P〈0.01）. Conclusion Thyroid weigh was main factor in 131I calculations pre-treatment.The RAIU＆EHL of therapeutic were lower than tracer dose,TGAb （TPOAb） played some role in hypothyroidism development.
出处
《中国现代医生》
2013年第20期45-46,49,共3页
China Modern Doctor
